Aspirin vs. Enoxaparin for Preventing Symptomatic Venous Thromboembolism in Hip or Knee Arthroplasty
                                                    Aspirin vs. Enoxaparin for Preventing Symptomatic Venous Thromboembolism in Hip or Knee Arthroplasty
Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial
JAMA. 2022 Aug 23;328(8):719-727.Synopsis
9711 patients with osteoarthritis undergoing a hip or knee arthroplasty procedure at one of 31 participating hospitals were randomized (in this hospital-level, cluster-randomized, crossover, non-inferiority trial) to receive aspirin (n=5675) or enoxaparin (n=4036) for the prevention of symptomatic venous thromboembolism (VTE). The primary outcome of interest was symptomatic VTE within 90 days, inc...
                To view the full content, login to your account,
or start your 30-day FREE Trial today.
            
            FREE TRIAL
            LOGIN
            Forgot Password?
    Explore some of our unlocked ACE Reports below!
                Learn about our AI Driven 
 High Impact Search Feature
    Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
                    
                
                                                        
                                                        
                                    LOGIN
                                
            
Join the Conversation
Please Login or Join to leave comments.